ImCheck Therapeutics SAS raises €48m
The €48m financing was co-led by Pfizer Ventures, the venture capital arm of Pfizer Inc., and Bpifrance, with the new investors Wellington Partners,...
Merck and 4SC collaborate in immunooncology
Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC...
BioVersys receives up to €8m from CARB-X
Privately-owned BioVersys AG, headquartered in Basel, is focusing on research and development of small molecules for multidrug-resistant bacterial...
Cellectis presents way to safer CAR-Ts
The company presented the in vitro "proof-of-concept" of their new CAR-T cells, in which they integrated a gene network that senses tumour...
HepaRegeniX: €11m for liver disease treatment
In preclinical studies, HepaRegeniX’ MKK4 inhibitor had demonstrated efficacy in liver regeneration and experimental acute and chronic liver disease...
Sherlock Bioscience and Mologic enter partnership
Mologic said it will invest a part of an expansion to its $4.9m grant from the Bill and Melinda-Gates Foundation to finance access to Sherlock's...
Big Pharma is cost driver of GAVI
MSF demanded the GAVI to immediately stop paying out funds from a remaining US$262m subsidy to Pfizer and GlaxoSmithKline (GSK) for the pneumococcal...